SITC 2021 | NEON-1 & NEON-2: ALPN-202 alone or with pembrolizumab in patients with advanced malignancies

ALPN-202 is a first-in-class conditional CD28 costimulator and dual PD-L1/CTLA-4 inhibitor. Meredith McKean, MD, Sarah Cannon Research Institute, Nashville, TN, comments on initial data from the NEON-1 trial (NCT04186637), a Phase I study of ALPN-202 monotherapy in patients with advanced malignancies and outlines preliminary data of ALPN-202 in combination with pembrolizumab. Preclinical data shows improvement in tumor cell reduction with the combination of ALPN-202 with pembrolizumab. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.